Document Detail


Influences of surface coatings and components of FePt nanoparticles on the suppression of glioma cell proliferation.
MedLine Citation:
PMID:  22848161     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Malignant gliomas are primary brain tumors with high rates of morbidity and mortality; they are the fourth most common cause of cancer death. Novel diagnostic and therapeutic techniques based on nanomaterials provide promising options in the treatment of malignant gliomas. In order to evaluate the potential of FePt nanoparticles (NPs) for malignant glioma therapy, FePt NPs with different surface coatings and components were tunably synthesized using oleic acid/oleylamine (OA/OA) and cysteines (Cys) as the capping agents, respectively. The samples were characterized using X-ray diffraction, transmission electron microscopy (TEM), X-ray photon spectroscopy, Fourier transform infrared spectroscopy, atomic absorption spectrum, and zeta potential. The influence of the surface coatings and components of the FePt NPs on the proliferation of glioma cells was assessed through MTT assay and TEM observation using three typical glioma cell lines (glioma U251 cells, astrocytoma U87 cells, and neuroglioma H4 cells) as in vitro models. The results showed that the proliferation of glioma cells was significantly suppressed by lipophilic FePt-OA/OA NPs in a time- and/or dose-dependent manner, while no or low cytotoxic effects were detected in the case of hydrophilic FePt-Cys NPs. The IC₅₀ value of FePt-OA/OA NPs on the three glioma cell lines was approximately 5-10 μg mL⁻¹ after 24 hours' incubation. Although the cellular uptake of FePt NPs was confirmed regardless of the surface coatings and components of the FePt NPs, the suppression of FePt NPs on glioma cell proliferation was dominantly determined by their surface coatings rather than their components. Therefore, these results demonstrate that, through engineering of the surface coating, FePt NPs can potentially be developed as novel therapeutic agents for malignant gliomas.
Authors:
Haiming Sun; Xiaohui Chen; Dan Chen; Mingyan Dong; Xinning Fu; Qian Li; Xi Liu; Qingzhi Wu; Tong Qiu; Tao Wan; Shipu Li
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2012-07-06
Journal Detail:
Title:  International journal of nanomedicine     Volume:  7     ISSN:  1178-2013     ISO Abbreviation:  Int J Nanomedicine     Publication Date:  2012  
Date Detail:
Created Date:  2012-07-31     Completed Date:  2013-02-21     Revised Date:  2013-07-12    
Medline Journal Info:
Nlm Unique ID:  101263847     Medline TA:  Int J Nanomedicine     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  3295-307     Citation Subset:  IM    
Affiliation:
State Key Laboratory of Advanced Technology for Materials Synthesis and Processing and Biomedical Materials and Engineering Center, Wuhan University of Technology, Wuhan, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Amines / chemistry
Antineoplastic Agents / chemistry,  pharmacokinetics,  pharmacology*
Cell Line, Tumor
Cell Proliferation / drug effects
Cysteine / chemistry
Glioma / drug therapy*,  metabolism,  pathology*
Humans
Magnetite Nanoparticles / administration & dosage*,  chemistry
Oleic Acid / chemistry
Particle Size
Platinum / chemistry,  pharmacokinetics,  pharmacology*
Spectroscopy, Fourier Transform Infrared
Chemical
Reg. No./Substance:
0/Amines; 0/Antineoplastic Agents; 0/Magnetite Nanoparticles; 112-80-1/Oleic Acid; 52-90-4/Cysteine; 7440-06-4/Platinum; ZDQ1JWQ8DT/oleylamine
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Neurological disorders and therapeutics targeted to surmount the blood-brain barrier.
Next Document:  Solid lipid nanoparticles modified with stearic acid-octaarginine for oral administration of insulin...